Previous close | 236.78 |
Open | 240.66 |
Bid | 243.14 x 1000 |
Ask | 243.45 x 800 |
Day's range | 239.46 - 243.64 |
52-week range | 189.40 - 301.34 |
Volume | |
Avg. volume | 571,258 |
Market cap | 35.632B |
Beta (5Y monthly) | 0.47 |
PE ratio (TTM) | 45.96 |
EPS (TTM) | N/A |
Earnings date | N/A |
Forward dividend & yield | 1.68 (0.69%) |
Ex-dividend date | 11 May 2022 |
1y target est | N/A |
Acquisition lays foundation to build ResMed’s digital sleep medicine portfolio in Germanysomnio digital health application focused on improving sleep in patients with diagnosed insomnia, filling care gap and providing alternative to prevailing drug therapy mementor to be integrated into ResMed in Germany as a separate business segment and will serve as a platform for further developments in the field of digital health MARTINSRIED, Germany and LEIPZIG, Germany, Aug. 02, 2022 (GLOBE NEWSWIRE) -- R
SAN DIEGO, July 14, 2022 (GLOBE NEWSWIRE) -- ResMed (NYSE: RMD, ASX: RMD) today announced it plans to release financial and operational results for the fourth quarter of fiscal year 2022 on Thursday, August 11, 2022, after the New York Stock Exchange closes. Following the release, ResMed management will host a webcast to discuss these results. Other forward-looking and material information may also be discussed during this webcast. Earnings webcast details: • Location:http://investor.resmed.com•
Lucile Blaise, President, Sleep & Respiratory Care, ResMed Lucile Blaise, President, Sleep & Respiratory Care, ResMed Blaise is a medtech industry thought leader with over 25 years’ experienceA board member of MedTech Europe since 2020; President of the Snitem, France’s premier medtech associationPromotion effective July 1 SAN DIEGO, June 28, 2022 (GLOBE NEWSWIRE) -- ResMed (NYSE: RMD, ASX: RMD) today announced the promotion of Lucile Blaise to President of Sleep & Respiratory Care, effective Ju